Poster Session A
Epidemiology, health policy and outcomes
Victoria Werth, MD
University of Pennsylvania
Wynnewood, PA, United States
Disclosure(s): AbbVie: Consultant (Terminated, March 17, 2022); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Anaptysbio: Consultant (Ongoing); Argenx: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing); Celgene: Consultant (Terminated, October 21, 2021), Grant/Research Support (Terminated, October 21, 2021); Corbus: Grant/Research Support (Terminated, January 11, 2021); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Horizon Therapeutics: Grant/Research Support (Ongoing); Idera: Consultant (Ongoing); Incyte: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kyowa Kirin: Consultant (Ongoing); Lilly: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Ongoing); Regeneron: Grant/Research Support (Ongoing); Resolve: Consultant (Ongoing), Consultant (Ongoing); Rome Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Ventus: Grant/Research Support (Ongoing); Viela: Consultant (Terminated, May 6, 2022), Grant/Research Support (Terminated, May 6, 2022); Xencor: Consultant (Ongoing)